To the full analysis
Buyback calculator for Achieve Life Sciences
Achieve Life Sciences stock: key metrics
ACHVMargins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 100.0% | −117.4% | −105.2% |
| 2007 | 100.0% | −75.7% | −64.9% |
| 2008 | 100.0% | −31.1% | −20.9% |
| 2009 | 100.0% | −9.7% | 21.4% |
| 2010 | 100.0% | −108.3% | −92.4% |
| 2011 | 100.0% | −405.5% | −267.0% |
| 2012 | 100.0% | −129.3% | −105.0% |
| 2013 | 100.0% | −118.2% | −106.6% |
| 2014 | 100.0% | −108.7% | −96.8% |
| 2015 | 100.0% | −103.3% | −92.5% |
| 2016 | 100.0% | −418.6% | −397.6% |
| 2017 | no data | no data | no data |
| 2018 | no data | no data | no data |
| 2019 | no data | no data | no data |
| 2020 | no data | no data | no data |
| 2021 | no data | no data | no data |
| 2022 | no data | no data | no data |
| 2023 | no data | no data | no data |
| 2024 | no data | no data | no data |
| 2025 | no data | no data | no data |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | −54.7% | −42.7% | −34.4% |
| 2007 | −40.9% | −27.5% | −28.9% |
| 2008 | −39.3% | −19.2% | −28.4% |
| 2009 | 23.9% | −9.6% | 7.9% |
| 2010 | −28.5% | −25.4% | −14.0% |
| 2011 | −47.5% | −34.9% | −21.6% |
| 2012 | −31.9% | −38.1% | −25.7% |
| 2013 | −85.6% | −50.2% | −57.2% |
| 2014 | −77.0% | −62.0% | −46.6% |
| 2015 | −44.9% | −41.2% | −28.9% |
| 2016 | −100.0% | −58.3% | −73.3% |
| 2017 | −100.0% | −37.8% | −100.0% |
| 2018 | −80.3% | −85.4% | −66.5% |
| 2019 | −90.8% | −76.8% | −77.8% |
| 2020 | −39.3% | −41.9% | −36.4% |
| 2021 | −100.0% | −65.1% | −69.8% |
| 2022 | −100.0% | −95.6% | −100.0% |
| 2023 | 200.0% | no data | −100.0% |
| 2024 | −100.0% | no data | −100.0% |
| 2025 | −100.0% | no data | −100.0% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 9 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Sep 2009)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.